Upfront Treatment for Breast Cancer with Node Metastases
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
Recruiting
Phase 2
Interventional Study
Breast Cancer
Axillary Nodal Disease
Female Breast Cancer
Axilla; Breast
Mastectomy; Lymphedema
Tumor, Breast
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 45 and older
- Sex
- Female
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 45 (estimated)
- Sponsor
- Alice Chung · Other
Who this trial is looking for
This trial is looking for women aged 45 and older with specific types of breast cancer that have spread to lymph nodes. Participants will undergo surgery followed by additional treatment and will be monitored for outcomes.
Are You a Good Fit for This Trial?
You may be able to join if
- I am a woman aged 45 or older
- I have been diagnosed with T1-2N0 ER+ invasive breast cancer
- I have biopsy-proven axillary nodal disease detected by ultrasound
- I can provide written consent to participate in the study
You may not be able to join if
- I have palpable lymph nodes found during a physical exam
- I have Her2+ or ER- invasive breast cancer
- I have more than 3 mm extranodal extension on my biopsy
- I have more than 2 suspicious lymph nodes shown on imaging
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Women age ≥ 45
* Clinical T1-2N0 ER+ invasive breast cancer
* US detected biopsy proven axillary nodal disease
* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
* Palpable nodes on physi…
Contacts